0000000000445324

AUTHOR

Massimiliano Missere

showing 2 related works from this author

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine ther…

2013

Background: Due to the limited data available in literature, the aim of this multi-centre study was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up of 18 months. Methods: Among the first 1135 TM patients in the MIOT (Myocardial Iron Overload in Thalassemia) network, we evaluated those who had received either combined regimen (DFO + DFP, N=51) or DFP (N=39) and DFO (N=74) monotherapies between the two CMR scans. Iron overload was measured by T2* multiecho technique. Biventricular function parameters were qua…

MaleLiver Iron ConcentrationTime FactorsThalassemiaVentricular Function Leftchemistry.chemical_compoundMedicineDeferiproneProspective StudiesMedicine(all)Ejection fractionRadiological and Ultrasound TechnologyBeta thalassemiaDeferoxamineTreatment OutcomeItalyLiverCardiologyThalassemiaDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineDeferiproneCardiomyopathiesmedicine.drugAdultmedicine.medical_specialtyCombination therapyPyridonesChelation therapyMagnetic Resonance Imaging CineDeferoxamineIron Chelating AgentsYoung AdultPredictive Value of TestsInternal medicineHumansRadiology Nuclear Medicine and imagingChelation therapyAnalysis of VarianceChi-Square Distributionbusiness.industryResearchMyocardiumbeta-ThalassemiaStroke Volumemedicine.diseaseSurgerychemistryVentricular Function RightCardiovascular magnetic resonancebusinessJournal of Cardiovascular Magnetic Resonance
researchProduct

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative…

2010

Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major patients by means of quantitative magnetic resonance imaging. Design and Methods From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalasse…

medicine.medical_specialtyLiver Iron ConcentrationthalassemiaThalassemiairon chelation therapycardiac magnetic resonance imagingGastroenterologythalassemia; iron chelation therapy; cardiac magnetic resonance imagingNOchemistry.chemical_compoundCardiac magnetic resonance imagingInternal medicinemedicinemedicine.diagnostic_testbusiness.industryDeferasiroxBeta thalassemiaMagnetic resonance imagingHematologymedicine.diseaseSurgeryDeferoxaminechemistrybusinessDeferipronemedicine.drug
researchProduct